Metal ion mediated aggregation of Alzheimer's disease peptides and proteins in solutions and at surfaces
J Feng, Y She, C Li, L Shen - Advances in Colloid and Interface Science, 2023 - Elsevier
Although the pathogenesis of Alzheimer's disease (AD) is still unclear, abnormally high
concentrations of metal ions, like copper, iron and zinc, were found in senile plaques of AD …
concentrations of metal ions, like copper, iron and zinc, were found in senile plaques of AD …
[HTML][HTML] Peptide aptamer targeting Aβ–PrP–Fyn axis reduces Alzheimer's disease pathologies in 5XFAD transgenic mouse model
T Ali, AN Klein, A Vu, MI Arifin, S Hannaoui… - Cellular and Molecular …, 2023 - Springer
Currently, no effective therapeutics exist for the treatment of incurable neurodegenerative
diseases such as Alzheimer's disease (AD). The cellular prion protein (PrPC) acts as a high …
diseases such as Alzheimer's disease (AD). The cellular prion protein (PrPC) acts as a high …
Mitochondria transfer as a potential therapeutic mechanism in Alzheimer's disease-like pathology
M Mishra, S Raik, V Rattan, S Bhattacharyya - Brain Research, 2023 - Elsevier
Alzheimer's disease (AD) is an age-related neurodegenerative disorder characterized by
cognition decline and memory deterioration. The molecular pathogenic mechanism of AD is …
cognition decline and memory deterioration. The molecular pathogenic mechanism of AD is …
SorCS1 inhibits amyloid-β binding to neurexin and rescues amyloid-β–induced synaptic pathology
AK Lee, N Yi, H Khaled, B Feller… - Life Science …, 2023 - life-science-alliance.org
Amyloid-β oligomers (AβOs), toxic peptide aggregates found in Alzheimer's disease, cause
synapse pathology. AβOs interact with neurexins (NRXs), key synaptic organizers, and this …
synapse pathology. AβOs interact with neurexins (NRXs), key synaptic organizers, and this …
[图书][B] Glutamatergic and Metabolic Dysregulation in Alzheimer's Disease Mouse Models: The Impact of Prodromal Riluzole Treatment
C Findley - 2023 - search.proquest.com
Prior research supports a strong link between Alzheimer's disease (AD) and metabolic
dysfunction that involves a multi-directional interaction between glucose, glutamatergic …
dysfunction that involves a multi-directional interaction between glucose, glutamatergic …
[HTML][HTML] Capturing transient peptide assemblies associated with Alzheimer's disease: Native mass spectrometry studies of amyloid-β oligomerization
N Österlund - 2023 - diva-portal.org
Correct folding of proteins is essential for maintaining a functional living cell. Misfolding and
aggregation of proteins, where non-native intermolecular interactions form large and highly …
aggregation of proteins, where non-native intermolecular interactions form large and highly …
Inhibition of Amyloid Beta Oligomer Formation, Binding, and Downstream Tau Phosphorylation: Three Potential Therapeutic Approaches for Alzheimer's Disease
EA Johnson - 2023 - search.proquest.com
Amyloid beta oligomers (AβOs) are a key instigator of neurodegeneration in Alzheimer's
disease (AD). The work presented in this thesis includes three disease-modifying …
disease (AD). The work presented in this thesis includes three disease-modifying …
Passive Immunisierung mit dem monoklonalen Antikörper NT4X am Tg4-42-Mausmodell für die sporadische Form der Alzheimer Erkrankung
P Henniges - 2023 - ediss.uni-goettingen.de
Als „Demenz “wird eine chronische Hirnerkrankung bezeichnet, die in ihrem Verlauf Einfluss
auf die Kognition nimmt und zu einer progredienten geistigen Degeneration führt und durch …
auf die Kognition nimmt und zu einer progredienten geistigen Degeneration führt und durch …
[PDF][PDF] “Transitional cognitive dysfunction” or “Transitional cognitive decline” for ultra-early screening of Alzheimer's disease?
P Wei - researchgate.net
Alzheimer's disease imposes a severe burden. Alzheimer's pathology can be assessed and
defined by Aβ and tau biomarkers. Pathogenesis of Alzheimer's disease is a continuum that …
defined by Aβ and tau biomarkers. Pathogenesis of Alzheimer's disease is a continuum that …
Devices, systems, and methods for evaluating cardiac parameters
J Hickman, M Stancescu, P Molnar, C Long… - US Patent …, 2023 - Google Patents
2020-09-29 Assigned to UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION,
INC. reassignment UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC …
INC. reassignment UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC …